Abnormal Sialylation Promotes Chemotherapy Resistance in Bladder Cancer via the PI3K-AKT-mTOR Signaling Pathway
Cancers · 24.05.2026 · 18 (11) · 1713
DOI: 10.3390/cancers18111713 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 24.05.2026. Verfasst von Junlong Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chongqing Science and Technology Commission.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Aberrant glycosylation is closely associated with tumor progression, changes in the tumor microenvironment, and chemoresistance. This study aimed to identify prognostic sialylation-related genes in bladder cancer and define the role of ST3GAL6 in gemcitabine–cisplatin resistance.
Methods
Molecular subtype analysis, prognostic analysis, and risk model construction were performed for sialylation-related genes using transcriptomic data and clinical information from the TCGA database. GC-resistant bladder cancer cell models were established for transcriptomic sequencing and untargeted metabolomic analysis. Cell proliferation and drug sensitivity assays were performed to evaluate the function of ST3GAL6. The regulatory relationship between IGF2BP3, ST3GAL6, and the PI3K pathway was further assessed by combining database analysis with molecular experiments.
Results
Sialylation-related molecular patterns were associated with patient prognosis and tumor microenvironment features, particularly fibroblast-related characteristics, in bladder cancer. The key model gene ST3GAL6 was upregulated in bladder cancer tissues and was closely associated with prognosis. In GC-resistant bladder cancer cells, ST3GAL6 expression was significantly increased and accompanied by enhanced sialylation activity. ST3GAL6 promoted bladder cancer cell proliferation and reduced sensitivity to cisplatin and gemcitabine, at least in part through the PI3K-AKT-mTOR pathway. IGF2BP3 was also upregulated in resistant cells, is positively correlated with ST3GAL6, and may help maintain ST3GAL6’s expression by stabilizing its mRNA.
Conclusions
Our findings suggest that aberrant sialylation is involved in bladder cancer progression and GC resistance. The IGF2BP3-ST3GAL6-PI3K/AKT/mTOR signaling axis may contribute to this process and may serve as a potential biomarker and therapeutic target in bladder cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Förderung
- Chongqing Science and Technology Commission
Zitieren
APA
Zhu, J., Wang, A., Tong, H., Sun, Y., Li, T., Wu, L., Zhang, X., Qin, Z., & He, W. (2026). Abnormal Sialylation Promotes Chemotherapy Resistance in Bladder Cancer via the PI3K-AKT-mTOR Signaling Pathway. Cancers, 18(11), 1713. https://doi.org/10.3390/cancers18111713
Vancouver
Zhu J, Wang A, Tong H, Sun Y, Li T, Wu L, et al. Abnormal Sialylation Promotes Chemotherapy Resistance in Bladder Cancer via the PI3K-AKT-mTOR Signaling Pathway. Cancers. 2026;18(11):1713. doi:10.3390/cancers18111713
BibTeX
@article{Zhu2026,
author = {Zhu, Junlong and Wang, Aimin and Tong, Hang and Sun, Yan and Li, Tinghao and Wu, Linfeng and Zhang, Xiaoyu and Qin, Zijia and He, Weiyang},
title = {Abnormal Sialylation Promotes Chemotherapy Resistance in Bladder Cancer via the PI3K-AKT-mTOR Signaling Pathway},
journal = {Cancers},
year = {2026},
volume = {18},
number = {11},
pages = {1713},
doi = {10.3390/cancers18111713}
}
EUVIMED